International Edition
Latest News
Health

FDA, PCMC Clash Over YCM Hospital Drug Seizure and Valuation

The Food and Drug Administration seized medicines worth an estimated ₹1.72 crore from the central drug store at Yashwantrao Chavan Memorial Hospital on November 4, the regulator said. The Pimpri-Chinchwad Municipal Corporation disputed the characterization and the valuation…

FDA, PCMC Clash Over YCM Hospital Drug Seizure and Valuation

The Food and Drug Administration seized medicines worth an estimated ₹1.72 crore from the central drug store at Yashwantrao Chavan Memorial Hospital on November 4, the regulator said.

The Pimpri-Chinchwad Municipal Corporation disputed the characterization and the valuation the same day. Civic officials said the stock had already been isolated months earlier after a patient complaint and was worth only ₹11.95 lakh, according to The Indian Express.

FDA joint commissioner Girish Hukare told The Indian Express the action was a raid conducted as follow-up after laboratory tests found the medicines substandard. “We had indeed conducted a raid as a follow up measure after we found that the medicines given for testing were not upto the required standards,” Hukare said.

PCMC additional municipal commissioner Kuldeep Jangam told The Indian Express the civic body had acted on its own in February after a patient reported a medicine was ineffective. Samples were sent to the FDA on February 23 and the report arrived July 16, he said.

Sequence of events

The dispute traces back to a complaint received on February 14 from the civic-run Thergaon Hospital about Cap. B-Complex with Zinc (CareZinc), PCMC said in a statement. The corporation sent a letter to the FDA on February 23 requesting it take custody of the stock for testing. The medicine had been supplied by M/s Vinayak Pharma, Pune, manufactured by Inducare Pharmaceuticals and Research Foundation, Jejuri MIDC, Pune.

YCM Hospital Drug Stock Seized By FDA, PCMC Disputes ₹1.72 Crore Valuation
Photo: Pune Mirror

PCMC said it restricted use of the stock and set it aside the same day. FDA officials collected samples for testing on February 23, according to the civic body.

The FDA laboratory report dated July 16 found the medicine not of standard quality. PCMC then blacklisted Inducare Pharmaceuticals and Research Foundation for three years and barred the supplier M/s Shri Vinayak Pharma for three years.

FDA drug inspector S.S. Bugad collected samples from the hospital’s central store for testing, Pune Mirror reported. During document examination, officials found the manufacturer did not hold valid manufacturing permissions for several medicines supplied to the hospital. A show-cause notice was issued to the company on October 29.

The FDA seized 10 categories of medicines from the hospital under the Drugs and Cosmetics Act, 1940, Pune Mirror reported. Laboratory analysis identified deficiencies in assay, dissolution, description, uniformity of weight and labelling. The regulator also seized medicines worth around ₹17.58 lakh from the Jejuri manufacturing unit.

Valuation and terminology at odds

PCMC said the value of the 11 medicine stocks seized from the hospital was ₹11,95,863 as per tender value and that no payment had been made to the supplier.

“No raid was conducted by the Food and Drug Administration (FDA) regarding the medicine stock at YCM Hospital,” said Dr Laxman Gophane, health medical officer, PCMC. “Upon receiving a complaint about medicine quality, the Municipal Corporation took the initiative on its own and sent the medicine stock to the FDA for testing.”

The FDA maintained the market value of the hospital stock was ₹1.72 crore. Hukare said the four-month testing delay was due to volume: “Since we get medicines for testing from several places, it took time to carry out the testing of medicines supplied by PCMC. We had immediately asked the PCMC to keep aside the medicine on which complaint had been received.”

FDA files court cases against manufacturers

The FDA said it will file court cases against the manufacturers who supplied the substandard medicines to PCMC. The manufacturer was served a notice over production and sale of medicines without necessary permissions and the department is preparing to initiate court proceedings, Pune Mirror reported.

PCMC maintains the medicines had already been isolated and action against the manufacturer and supplier taken earlier. The differing figures and the characterization of the November 4 action remain unresolved between the two agencies.

About the author: Health Desk

Health Desk at Archynewsy.